Modular Medical, Inc. (NASDAQ: MODD) announced a 1‑for‑30 reverse stock split that will take effect at 5:30 a.m. ET on March 31, 2026. The split consolidates every 30 shares into one, a move intended to lift the company’s share price toward Nasdaq’s $1.00 minimum bid price requirement and to improve liquidity for shareholders.
Prior to the split, the company had approximately 139,810,797 shares outstanding. After the split, the outstanding shares will be about 4,660,360. Fractional shares resulting from the conversion will be paid in cash. The company’s CUSIP is 60785L306, and all outstanding warrants and options will be adjusted on a pro‑rata basis—shares divided by 30 and exercise prices multiplied by 30—so that holders retain the same economic exposure.
Modular Medical received a 180‑day extension from Nasdaq on December 31, 2025, giving the company until June 29, 2026 to regain compliance with the minimum bid price rule. Failure to meet that deadline could trigger delisting. The reverse split does not change the company’s market capitalization, but it signals the company’s ongoing effort to meet listing standards while operating in a capital‑constrained environment.
The company is a development‑stage medical‑device firm focused on insulin delivery technology. Its flagship product, the Pivot tubeless insulin delivery system, has completed a U.S. FDA 510(k) submission and manufacturing validation, and the company is pursuing CE Mark certification for international commercialization. These milestones are critical for the company’s future revenue potential, but the product is not yet commercially available.
Financially, Modular Medical is rated as “WEAK.” The auditor has raised going‑concern doubts, and the company’s losses have been increasing over the past five years. The company has relied on equity offerings to raise capital, which has diluted existing shareholders. The stock has declined sharply over the past year, reflecting the market’s perception of the company’s financial challenges.
The reverse split is a tactical response to Nasdaq’s listing requirements and an attempt to improve liquidity, but it also underscores the company’s fragile financial position. Investors should view the split as a short‑term compliance measure rather than a sign of improved fundamentals. The company’s future prospects will depend on the successful commercialization of its Pivot system and its ability to raise capital without further diluting shareholders.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.